

Part D Coverage of Insulin and Biosimilars



Medicare Advantage Part D and Prescription Drug Plan | 2026



In 2026, Medicare Part D will continue capping the cost-sharing of insulin products to either a **\$35 copay per one-month supply, 25% of the drug's contracted price or 25% of the Medicare-negotiated Maximum Fair Price (MFP), whichever is lowest.** The cost-sharing is capped regardless of formulary tier, beneficiary's benefit phase or deductible. Our members can have peace of mind knowing their insulin cost will be low, consistent and predictable.

Insulins and biosimilars: What you need to know

Recently, insulin was reclassified as a biologic, which is defined as a complex molecule derived from living sources. This change means insulin is now regulated under different U.S. Food and Drug Administration rules, allowing companies to produce **biosimilars**, which are highly similar versions of brand-name biologics proven to be equally safe and effective. Like generics, biosimilars can lower costs for the Medicare Part D program and its beneficiaries.

- Biologics are derived from the same types of living sources.
- They provide the same therapeutic effects when treating diseases or medical conditions.
- Biologics are administered at the same strength and dosage.
- They are not expected to cause new or worsening side effects.

Covered insulin products	Insulin category
Merilog SoloStar 100 unit/mL pen injector	Rapid-acting; biosimilar product
Merilog 100 unit/mL vial	Rapid-acting; biosimilar product
NovoLog FlexPen 100 unit/mL pen injector	Rapid-acting
NovoLog 100 unit/mL vial	Rapid-acting
NovoLog Penfill 100 unit/mL cartridge	Rapid-acting
Fiasp FlexTouch 100 unit/mL pen injector	Rapid-acting
Fiasp 100 unit/mL vial	Rapid-acting
Fiasp Penfill 100 unit/mL cartridge	Rapid-acting

(continued)

Covered insulin products	Insulin category
Humulin R KwikPen 500 unit/mL pen injector	Regular-/short-acting
Novolin R FlexPen 100 unit/mL pen injector	Regular-/short-acting
Novolin R 100 unit/mL vial	Regular-/short-acting
Novolin N FlexPen 100 unit/mL pen injector	Intermediate-acting
Novolin N 100 unit/mL vial	Intermediate-acting
Lantus SoloStar 100 Unit/mL pen injector	Long-acting
Lantus 100 Unit/mL vial	Long-acting
Insulin Glargine Max SoloStar 300 unit/mL pen injector	Long-acting
Insulin Glargine SoloStar 300 unit/mL pen injector	Long-acting
Insulin Glargine-yfgn 100 unit/mL pen injector	Long-acting; biosimilar product
Insulin Glargine-yfgn 100 unit/mL vial	Long-acting; biosimilar product
NovoLog Mix 70-30 FlexPen 100 unit/mL pen injector	Pre-mixed insulin combination
NovoLog Mix 70-30 100 unit/mL vial	Pre-mixed insulin combination
Novolin 70-30 FlexPen 100 unit/mL pen injector	Pre-mixed insulin combination
Novolin 70-30 100 unit/mL vial	Pre-mixed insulin combination
Soliqua 100 unit-33 mcg/mL pen injector	Insulin/GLP-1 combination

6199207_NA6PCARFLYE
Internal Approval 03202026/26-344m (3/26)

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.